Clinical Significance of Major Angiogenesis-Related Effectors in Patients with Metastatic Breast Cancer Treated with Trastuzumab-based Regimens
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Purpose: Angiogenesis is a crucial phenomenon in the development and progression of breast cancer (BC), but the clinical significance of angiogenesis-related proteins in metastatic BC remains unknown. This study investigates the prognostic value of vascular endothelial growth factor receptors 1, 2, 3 (VEGFR1, VEGFR2, VEGFR3) as well as vascular endothelial growth factors A and C (VEGFA and VEGFC) in metastatic BC patients treated with trastuzumab-based regimens. Materials and methods: Two hundred female patients were included. Protein and mRNA expression of the studied angiogenesis-related factors were evaluated by immunohistochemistry and quantitative polymerase chain reaction, respectively. Results: High expression of VEGFA, VEGFC, VEGFR1, VEGFR2, and VEGFR3 in the tumor cells was observed in 43.5%, 24.2%, 36%, 29.5%, and 43%, respectively. Stromal elements expressed high levels of VEGFA, VEGFC, VEGFR1, VEGFR2, and VEGFR3 in 78.9%, 93.3%, 90.7%, 90.2%, and 74.8% of tumors with available data. High tumor cell expression of VEGFR1 was a favorable prognosticator for survival among patients with human epidermal growth factor receptor 2 (HER2)-positive tumors (hazard ratio [HR], 0.55; p=0.013). A trend towards longer progression-free survival was detected univariately for patients with HER2-negative tumors and high expression of VEGFR2 (HR, 0.60; p=0.059). Conclusion: VEGFR1 and VEGFR2 seem to have significant prognostic value in BC patients with metastatic disease treated with trastuzumab-based regimens.
Abstract
Purpose: Angiogenesis is a crucial phenomenon in the development and progression of breast cancer (BC), but the clinical significance of angiogenesis-related proteins in metastatic BC remains unknown. This study investigates the prognostic value of vascular endothelial growth factor receptors 1, 2, 3 (VEGFR1, VEGFR2, VEGFR3) as well as vascular endothelial growth factors A and C (VEGFA and VEGFC) in metastatic BC patients treated with trastuzumab-based regimens. Materials and methods: Two hundred female patients were included. Protein and mRNA expression of the studied angiogenesis-related factors were evaluated by immunohistochemistry and quantitative polymerase chain reaction, respectively. Results: High expression of VEGFA, VEGFC, VEGFR1, VEGFR2, and VEGFR3 in the tumor cells was observed in 43.5%, 24.2%, 36%, 29.5%, and 43%, respectively. Stromal elements expressed high levels of VEGFA, VEGFC, VEGFR1, VEGFR2, and VEGFR3 in 78.9%, 93.3%, 90.7%, 90.2%, and 74.8% of tumors with available data. High tumor cell expression of VEGFR1 was a favorable prognosticator for survival among patients with human epidermal growth factor receptor 2 (HER2)-positive tumors (hazard ratio [HR], 0.55; p=0.013). A trend towards longer progression-free survival was detected univariately for patients with HER2-negative tumors and high expression of VEGFR2 (HR, 0.60; p=0.059). Conclusion: VEGFR1 and VEGFR2 seem to have significant prognostic value in BC patients with metastatic disease treated with trastuzumab-based regimens.
참고문헌 (27)
- Momenimovahed Z, "Epidemiological characteristics of and risk factors for breast cancer in the world", Breast Cancer(Dove Med Press), 11, pp.151~164 (2019)
- Harbeck N, "Breast cancer", Nat Rev Dis Primers, 5, pp.66~ (2019)
- Slamon DJ, "Human breast cancer : correlation of relapse and survival with amplification of the HER-2", neu oncogene, 1987, pp.235, 177~182
- Slamon DJ, "Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2", N Engl J Med, 344, pp.783~792 (2001)
- Madu CO, "Angiogenesis in breast cancer progression, diagnosis, and treatment", J Cancer, 11, pp.4474~4494 (2020)
- Alameddine RS, "Crosstalk between HER2 signaling and angiogenesis in breast cancer : molecular basis, clinical applications and challenges", Curr Opin Oncol, 25, pp.313~324 (2013)
- World Medical Association, "World Medical Association Declaration of Helsinki : ethical principles for medical research involving human subjects", JAMA, 310, pp.2191~2194 (2013)
- Linardou H, "Prognostic significance of VEGFC and VEGFR1 mRNA expression according to HER2 status in breast cancer : a study of primary tumors from patients with high-risk early breast cancer participating in a randomized Hellenic Cooperative Oncology Group Trial", Anticancer Res, 35, pp.4023~4036 (2015)
- Fountzilas G, "Paclitaxel and bevacizumab as first line combined treatment in patients with metastatic breast cancer : the Hellenic Cooperative Oncology Group experience with biological marker evaluation", Anticancer Res, 31, pp.3007~3018 (2011)
- Gogas H, "MYC copy gain, chromosomal instability and PI3K activation as potential markers of unfavourable outcome in trastuzumab-treated patients with metastatic breast cancer", J Transl Med, 14, pp.136~ (2016)
- Hennig G, "Automated extraction of DNA and RNA from a single formalin-fixed paraffin-embedded tissue section for analysis of both single-nucleotide polymorphisms and mRNA expression", Clin Chem, 56, pp.1845~1853 (2010)
- Lebok P, "Loss of membranous VEGFR1 expression is associated with an adverse phenotype and shortened survival in breast cancer", Mol Med Rep, 14, pp.1443~1450 (2016)
- Ghosh S, "High levels of vascular endothelial growth factor and its receptors(VEGFR-1, VEGFR-2, neuropilin-1)are associated with worse outcome in breast cancer", Hum Pathol, 39, pp.1835~1843 (2008)
- Kosaka Y, "Vascular endothelial growth factor receptor-1 mRNA overexpression in peripheral blood as a useful prognostic marker in breast cancer", Breast Cancer Res, 14, pp.R140~ (2012)
- Ning Q, "Vascular endothelial growth factor receptor-1 activation promotes migration and invasion of breast cancer cells through epithelial-mesenchymal transition", PLoS One, 8, pp.e65217~ (2013)
- Aldridge SE, "Vascular endothelial growth factor acts as an osteolytic factor in breast cancer metastases to bone", Br J Cancer, 92, pp.1531~1537 (2005)
- Kaplan RN, "VEGFR1-positive haematopoietic bone marrow progenitors initiate the pre-metastatic niche", Nature, 438, pp.820~827 (2005)
- Sadremomtaz A, "Dual blockade of VEGFR1 and VEGFR2 by a novel peptide abrogates VEGF-driven angiogenesis, tumor growth, and metastasis through PI3K", AKT and MAPK, 2 pathway, pp.Biochim Biophys Acta Gen Subj, 2018[DOI]
- Goussia A, "Associations of angiogenesis-related proteins with specific prognostic factors, breast cancer subtypes and survival outcome in early-stage breast cancer patients : a Hellenic Cooperative Oncology Group(HeCOG)trial", PLoS One, 13, pp.e0200302~ (2018)
- Esteva FJ, "Immunotherapy and targeted therapy combinations in metastatic breast cancer", Lancet Oncol, 20, pp.e175~e186 (2019)
- Kodack DP, "Combined targeting of HER2 and VEGFR2 for effective treatment of HER2-amplified breast cancer brain metastases", Proc Natl Acad Sci U S A, 109, pp.E3119~E3127 (2012)
- Yan JD, "Expression and prognostic significance of VEGFR-2 in breast cancer", Pathol Res Pract, 211, pp.539~543 (2015)
- Koutras A, "Evaluation of the prognostic value of all four HER family receptors in patients with metastatic breast cancer treated with trastuzumab : a Hellenic Cooperative Oncology Group(HeCOG)study", PLoS One, 13, pp.e0207707~ (2018)
- Paik S, "Real-world performance of HER2 testing : National Surgical Adjuvant Breast and Bowel Project experience", J Natl Cancer Inst, 94, pp.852~854 (2002)
- Roche PC, "Concordance between local and central laboratory HER2 testing in the breast intergroup trial N9831", J Natl Cancer Inst, 94, pp.855~857 (2002)
- Griggs JJ, "Discordance between original and central laboratories in ER and HER2 results in a diverse, population-based sample", Breast Cancer Res Treat, 161, pp.375~384 (2017)
- Kaufman PA, "Assessing the discordance rate between local and central HER2 testing in women with locally determined HER2-negative breast cancer", Cancer, 120, pp.2657~2664 (2014)